Jesse A Doran1, Waseem Sajjad1, Marabel D Schneider1, Rohit Gupta1, Maria L Mackin1, Ronald G Schwartz2,3. 1. Cardiology Division, Department of Medicine, University of Rochester Medical Center, Box 679-N, Rochester, NY, 14642, USA. 2. Cardiology Division, Department of Medicine, University of Rochester Medical Center, Box 679-N, Rochester, NY, 14642, USA. ronald_schwartz@urmc.rochester.edu. 3. Nuclear Medicine Division, Department of Imaging Sciences, University of Rochester Medical Center, Rochester, NY, USA. ronald_schwartz@urmc.rochester.edu.
Abstract
BACKGROUND:Aminophylline shortages led us to compare intravenous (IV) aminophylline with IV and oral (PO) caffeine during routine pharmacologic stress testing with SPECT MPI. METHODS: We measured presence, duration, and reversal of adverse symptoms and cardiac events following regadenoson administration in consecutive patients randomized to IV aminophylline (100 mg administered over 30-60 seconds), IV caffeine citrate (60 mg infused over 3-5 minutes), or PO caffeine as coffee or diet cola. RESULTS:Of 241 patients, 152 (63%) receivedregadenoson reversal intervention. Complete (CR), predominant (PRE), orpartial (PR) reversal was observed in 99%. CR by IV aminophylline (87%), IV caffeine (87%), and PO caffeine (78%) were similar (P = NS). Time to CR (162 ± 12.6 seconds, mean ± SD) was similar in treatment arms. PO caffeine was inferior to IV aminophylline for CR + PRE. CONCLUSIONS: IV aminophylline and IV caffeine provide rapid, safe reversal of regadenoson-induced adverse effects during SPECT MPI. Oral caffeine appeared similarly effective for CR but not for the combined CR + PRE. Our results suggest PO caffeine may be an effective initial strategy for reversal of regadenoson, but IV aminophylline or IV caffeine should be available to optimize symptom reversal as needed.
RCT Entities:
BACKGROUND:Aminophylline shortages led us to compare intravenous (IV) aminophylline with IV and oral (PO) caffeine during routine pharmacologic stress testing with SPECT MPI. METHODS: We measured presence, duration, and reversal of adverse symptoms and cardiac events following regadenoson administration in consecutive patients randomized to IV aminophylline (100 mg administered over 30-60 seconds), IV caffeine citrate (60 mg infused over 3-5 minutes), or PO caffeine as coffee or diet cola. RESULTS: Of 241 patients, 152 (63%) received regadenoson reversal intervention. Complete (CR), predominant (PRE), or partial (PR) reversal was observed in 99%. CR by IV aminophylline (87%), IV caffeine (87%), and PO caffeine (78%) were similar (P = NS). Time to CR (162 ± 12.6 seconds, mean ± SD) was similar in treatment arms. PO caffeine was inferior to IV aminophylline for CR + PRE. CONCLUSIONS: IV aminophylline and IV caffeine provide rapid, safe reversal of regadenoson-induced adverse effects during SPECT MPI. Oral caffeine appeared similarly effective for CR but not for the combined CR + PRE. Our results suggest PO caffeine may be an effective initial strategy for reversal of regadenoson, but IV aminophylline or IV caffeine should be available to optimize symptom reversal as needed.
Authors: Z Gao; Z Li; S P Baker; R D Lasley; S Meyer; E Elzein; V Palle; J A Zablocki; B Blackburn; L Belardinelli Journal: J Pharmacol Exp Ther Date: 2001-07 Impact factor: 4.030
Authors: Sara L Partington; Viswanatha Lanka; Jon Hainer; Ron Blankstein; Hicham Skali; Daniel E Forman; Marcelo F Di Carli; Sharmila Dorbala Journal: J Nucl Cardiol Date: 2012-05-08 Impact factor: 5.952
Authors: Gong Zhao; Axel Linke; Xiaobin Xu; Manuel Ochoa; Francis Belloni; Luiz Belardinelli; Thomas H Hintze Journal: J Pharmacol Exp Ther Date: 2003-09-03 Impact factor: 4.030
Authors: Aiden Abidov; Vasken Dilsizian; Rami Doukky; W Lane Duvall; Christopher Dyke; Michael D Elliott; Fadi G Hage; Milena J Henzlova; Nils P Johnson; Ronald G Schwartz; Gregory S Thomas; Andrew J Einstein Journal: J Cardiovasc Magn Reson Date: 2018-12-20 Impact factor: 5.364
Authors: Mohammed Elsadany; Bryan Stringer; Josiah Bote; Khaled H Abdulla; Jesse A Doran; Ronald G Schwartz; W Lane Duvall Journal: J Nucl Cardiol Date: 2022-07-06 Impact factor: 3.872